908 Devices Inc. (NASDAQ:MASS) CFO Sells $23,952.24 in Stock

908 Devices Inc. (NASDAQ:MASS - Get Free Report) CFO Joseph H. Iv Griffith sold 10,236 shares of 908 Devices stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $2.34, for a total value of $23,952.24. Following the transaction, the chief financial officer now owns 109,870 shares of the company's stock, valued at approximately $257,095.80. This represents a 8.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

908 Devices Stock Performance

Shares of MASS stock traded down $0.19 on Friday, reaching $2.36. 255,683 shares of the company were exchanged, compared to its average volume of 1,146,142. 908 Devices Inc. has a 1 year low of $1.81 and a 1 year high of $7.91. The business has a 50-day moving average price of $2.34 and a 200 day moving average price of $3.22. The company has a market cap of $82.18 million, a price-to-earnings ratio of -1.33 and a beta of 0.99.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 908 Devices in a report on Saturday, February 1st. Stifel Nicolaus decreased their price objective on shares of 908 Devices from $17.00 to $6.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. Leerink Partners reissued a "market perform" rating and set a $4.00 target price (down from $12.00) on shares of 908 Devices in a research note on Wednesday, November 13th. Leerink Partnrs lowered 908 Devices from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, November 13th. Finally, Stephens reiterated an "overweight" rating and set a $6.00 price target on shares of 908 Devices in a research report on Wednesday, January 15th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $5.33.

Hedge Funds Weigh In On 908 Devices

Hedge funds have recently made changes to their positions in the company. 49 Wealth Management LLC raised its stake in 908 Devices by 16.2% in the 3rd quarter. 49 Wealth Management LLC now owns 31,099 shares of the company's stock valued at $108,000 after purchasing an additional 4,343 shares during the last quarter. State Street Corp raised its position in shares of 908 Devices by 1.2% in the third quarter. State Street Corp now owns 479,044 shares of the company's stock valued at $1,662,000 after buying an additional 5,704 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of 908 Devices by 1.2% in the third quarter. Geode Capital Management LLC now owns 567,788 shares of the company's stock worth $1,970,000 after buying an additional 6,634 shares in the last quarter. SG Americas Securities LLC acquired a new position in 908 Devices during the third quarter worth about $36,000. Finally, B. Riley Wealth Advisors Inc. purchased a new position in 908 Devices in the 3rd quarter worth approximately $45,000. Institutional investors and hedge funds own 88.06% of the company's stock.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.